Chimerix to Participate in September Investor Conferences
Garrett Nichols , M.D., M.S., Chief Medical Officer of Chimerix will present at theH.C. Wainwright 20th AnnualGlobal Investment Conference onThursday, September 6, 2018 at8:45 a.m. ET inNew York City .
A live audio webcast of Dr. Nichols’ presentation at the
In addition,
- Citi 13th Annual
Biotech Conference onWednesday September 5, 2018 inBoston , and, Morgan Stanley Global Healthcare Conference onWednesday, September 12, 2018 inNew York City .
About Chimerix
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology and compound library have produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and CMX521, the first clinical-stage direct-acting antiviral for the treatment and prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com.
CONTACT:
Investor Relations:
(919) 972-7115
ir@chimerix.com
or
Will O’Connor
Stern Investor Relations
will@sternir.com
(212) 362-1200
Media:
lmasonson@w20group.com
(917) 459-6164
Source: Chimerix, Inc.